Contact Us
Tildrakizumab Global Market Report 2025
Global Tildrakizumab Market Report 2025
Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF
Purchase This Report

Tildrakizumab Global Market Report 2025

By Indication (Plaque Psoriasis, Psoriatic Arthritis, Other Indications), By Dosage Form (Injectable, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Specialty Clinics, Homecare) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tildrakizumab Market Overview

• Tildrakizumab market size has reached to $1.57 billion in 2024

• Expected to grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%

• Growth Driver: Rising Prevalence Of Psoriasis Boosts Growth Of The Market

• Market Trend: Transforming Treatment With Monoclonal Antibody Injections

North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tildrakizumab Market?

Tildrakizumab is a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor. This inhibition prevents downstream inflammatory signaling, reducing the activation of pro-inflammatory cytokines and immune cells involved in autoimmune conditions such as plaque psoriasis.

The main indications of the tildrakizumab include plaque psoriasis, psoriatic arthritis, and other indications. Plaque psoriasis is a chronic autoimmune skin condition caused by the inflamed, and scaly patches of skin, known as plaques. The drug is available in injectable and oral forms and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It serves various end users, including hospitals, specialty clinics, and home care.

Tildrakizumab Market Size and growth rate 2025 to 2029: Graph

What Is The Tildrakizumab Market Size 2025 And Growth Rate?

The tildrakizumab market size has grown rapidly in recent years. It will grow from $1.57 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the rise in the demand for the psoriasis treatment, rise in psoriasis prevalence, high prevalence of alcohol and smoking consumption, increase in research and development activities, increase in healthcare expenditure.

What Is The Tildrakizumab Market Growth Forecast?

The tildrakizumab market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to growing prevalence of psoriasis, the rising initiative, rising prevalence of plaque psoriasis and psoriatic arthritis, growing awareness and education, high prevalence of alcohol and smoking consumption. Major trends in the forecast period include product innovations, combination therapies, shift toward biologic and targeted therapies, new injectable drugs, shift towards personalized medicine.

The forecast of 11.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of targeted psoriasis therapy by inflating prices of tildrakizumab autoinjectors manufactured in India and Switzerland, resulting in delayed treatment escalation and higher dermatology specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Tildrakizumab Market Segmented?

1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Other Indications

2) By Dosage Form: Injectable, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Specialty Clinics, Homecare

Subsegments:

1) By Plaque Psoriasis: Moderate Plaque Psoriasis, Severe Plaque Psoriasis, Treatment-Resistant Plaque Psoriasis

2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis, Enthesitis-related Psoriatic Arthritis

3) By Other Indications: Inflammatory Skin Disorders, Off-Label Autoimmune Conditions, Emerging Therapeutic Applications

What Is Driving The Tildrakizumab Market? Rising Prevalence Of Psoriasis Boosts Growth Of The Market

The growing prevalence of psoriasis is expected to propel the growth of the tildrakizumab market going forward. Psoriasis is a chronic autoimmune condition that causes rapid skin cell turnover, leading to red, scaly patches on the skin. The growing prevalence of psoriasis is attributed to genetic predisposition, immune system dysfunction, environmental triggers, and lifestyle factors such as stress, smoking, and obesity. Tildrakizumab treats psoriasis by specifically inhibiting interleukin-23 (IL-23), a cytokine that triggers excessive skin cell growth and inflammation, helping to reduce plaques, scaling, and redness. For instance, in May 2024, according to the National Center for Biotechnology Information, a US-based national library of medicine, in 2022, the prevalence of PsA was 0.221%, with an incidence rate of 13.54 per 100,000 population. This prevalence has tripled compared to previous estimates. Therefore, the growing prevalence of psoriasis is driving the growth of the tildrakizumab industry.

What Is Driving The Tildrakizumab Market? Improvement In Healthcare Facilities Drives Growth Of The Market

The improvement of healthcare facilities is expected to propel the growth of the tildrakizumab market going forward. Healthcare facilities are establishments that offer medical care and services, such as hospitals, clinics, and diagnostic centers, to treat and support patients. Healthcare facilities are improving due to several factors such as increased investment in healthcare infrastructure, a focus on patient-centered care, population growth, and aging. Enhancing healthcare facilities improves patient access to advanced biologic treatments, streamlines diagnosis and specialist referrals, ensures better cold chain management for biologics, and expands healthcare provider awareness, all of which collectively support the adoption and efficacy of tildrakizumab in treating chronic inflammatory conditions such as psoriasis. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the improvement of healthcare facilities is driving the growth of the tildrakizumab industry.

Who Are The Major Players In The Global Tildrakizumab Market?

Major companies operating in the tildrakizumab market are Sun Pharmaceutical Industries Ltd., Almirall S.A.

What Are The Key Trends Of The Global Tildrakizumab Market? Transforming Treatment With Monoclonal Antibody Injections

Major companies operating in the tildrakizumab market are focusing on development of innovative formulations such as monoclonal antibody injection to enhance treatment efficacy and improve patient outcomes. Monoclonal antibody injection refers to the administration of laboratory-produced antibodies designed to target specific antigens in the body for therapeutic or preventive purposes. For instance, in May 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, received approval from the Chinese health authority, National Medical Products Administration (NMPA), for tildrakizumab injection used in treatment of plaque psoriasis. It works by targeting interleukin-23 (IL-23), a cytokine involved in the inflammatory response that causes psoriasis. IL-23, tildrakizumab helps reduce inflammation and slow down excessive skin cell growth, improving symptoms such as redness, scaling, and plaque formation.

Need data on a specific region in this market?

What Is The Regional Outlook For The Global Tildrakizumab Market?

North America was the largest region in the tildrakizumab market in 2024. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tildrakizumab  Market?

The tildrakizumab market consists of sales of single-dose vials and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Tildrakizumab  Industry?

The tildrakizumab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tildrakizumab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Tildrakizumab Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.76 billion
Revenue Forecast In 2034 $2.72 billion
Growth Rate CAGR of 11.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The tildrakizumab market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Other Indications
2) By Dosage Form: Injectable, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Homecare Subsegments:
1) By Plaque Psoriasis: Moderate Plaque Psoriasis, Severe Plaque Psoriasis, Treatment-Resistant Plaque Psoriasis
2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis, Enthesitis-related Psoriatic Arthritis
3) By Other Indications: Inflammatory Skin Disorders, Off-Label Autoimmune Conditions, Emerging Therapeutic Applications
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Sun Pharmaceutical Industries Ltd., Almirall S.A.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Tildrakizumab Market Characteristics

3. Tildrakizumab Market Trends And Strategies

4. Tildrakizumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Tildrakizumab Growth Analysis And Strategic Analysis Framework

5.1. Global Tildrakizumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Tildrakizumab Market Growth Rate Analysis

5.4. Global Tildrakizumab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Tildrakizumab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Tildrakizumab Total Addressable Market (TAM)

6. Tildrakizumab Market Segmentation

6.1. Global Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plaque Psoriasis

Psoriatic Arthritis

Other Indications

6.2. Global Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injectable

Oral

6.3. Global Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.4. Global Tildrakizumab Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

6.5. Global Tildrakizumab Market, Sub-Segmentation Of Plaque Psoriasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Moderate Plaque Psoriasis

Severe Plaque Psoriasis

Treatment-Resistant Plaque Psoriasis

6.6. Global Tildrakizumab Market, Sub-Segmentation Of Psoriatic Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Peripheral Psoriatic Arthritis

Axial Psoriatic Arthritis

Enthesitis-related Psoriatic Arthritis

6.7. Global Tildrakizumab Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Inflammatory Skin Disorders

Off-Label Autoimmune Conditions

Emerging Therapeutic Applications

7. Tildrakizumab Market Regional And Country Analysis

7.1. Global Tildrakizumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Tildrakizumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tildrakizumab Market

8.1. Asia-Pacific Tildrakizumab Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tildrakizumab Market

9.1. China Tildrakizumab Market Overview

9.2. China Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tildrakizumab Market

10.1. India Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tildrakizumab Market

11.1. Japan Tildrakizumab Market Overview

11.2. Japan Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tildrakizumab Market

12.1. Australia Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tildrakizumab Market

13.1. Indonesia Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tildrakizumab Market

14.1. South Korea Tildrakizumab Market Overview

14.2. South Korea Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tildrakizumab Market

15.1. Western Europe Tildrakizumab Market Overview

15.2. Western Europe Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tildrakizumab Market

16.1. UK Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tildrakizumab Market

17.1. Germany Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tildrakizumab Market

18.1. France Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tildrakizumab Market

19.1. Italy Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tildrakizumab Market

20.1. Spain Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tildrakizumab Market

21.1. Eastern Europe Tildrakizumab Market Overview

21.2. Eastern Europe Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tildrakizumab Market

22.1. Russia Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tildrakizumab Market

23.1. North America Tildrakizumab Market Overview

23.2. North America Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tildrakizumab Market

24.1. USA Tildrakizumab Market Overview

24.2. USA Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tildrakizumab Market

25.1. Canada Tildrakizumab Market Overview

25.2. Canada Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tildrakizumab Market

26.1. South America Tildrakizumab Market Overview

26.2. South America Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tildrakizumab Market

27.1. Brazil Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tildrakizumab Market

28.1. Middle East Tildrakizumab Market Overview

28.2. Middle East Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tildrakizumab Market

29.1. Africa Tildrakizumab Market Overview

29.2. Africa Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tildrakizumab Market Competitive Landscape And Company Profiles

30.1. Tildrakizumab Market Competitive Landscape

30.2. Tildrakizumab Market Company Profiles

30.2.1. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Almirall S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Global Tildrakizumab Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Tildrakizumab Market

33. Recent Developments In The Tildrakizumab Market

34. Tildrakizumab Market High Potential Countries, Segments and Strategies

34.1 Tildrakizumab Market In 2029 - Countries Offering Most New Opportunities

34.2 Tildrakizumab Market In 2029 - Segments Offering Most New Opportunities

34.3 Tildrakizumab Market In 2029 - Growth Strategies

34.3.1 Market Trend Based Strategies

34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations

35.2. Currencies

35.3. Historic And Forecast Inflation Rates

35.4. Research Inquiries

35.5. The Business Research Company

35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Tildrakizumab Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Tildrakizumab Market, Sub-Segmentation Of Plaque Psoriasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Tildrakizumab Market, Sub-Segmentation Of Psoriatic Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Tildrakizumab Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Tildrakizumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Tildrakizumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Sun Pharmaceutical Industries Ltd. Financial Performance
  • Table 79: Almirall S.A. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Tildrakizumab Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Tildrakizumab Market, Sub-Segmentation Of Plaque Psoriasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Tildrakizumab Market, Sub-Segmentation Of Psoriatic Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Tildrakizumab Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Tildrakizumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Tildrakizumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Sun Pharmaceutical Industries Ltd. Financial Performance
  • Figure 79: Almirall S.A. Financial Performance

Frequently Asked Questions

Tildrakizumab is a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor. This inhibition prevents downstream inflammatory signaling, reducing the activation of pro-inflammatory cytokines and immune cells involved in autoimmune conditions such as plaque psoriasis. For further insights on this market, request a sample here

The market major growth driver - Rising Prevalence Of Psoriasis Boosts Growth Of The Market. For further insights on this market, request a sample here

The tildrakizumab market size has grown rapidly in recent years. It will grow from $1.57 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the rise in the demand for the psoriasis treatment, rise in psoriasis prevalence, high prevalence of alcohol and smoking consumption, increase in research and development activities, increase in healthcare expenditure. The tildrakizumab market size is expected to see rapid growth in the next few years. It will grow to " $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to growing prevalence of psoriasis, the rising initiative, rising prevalence of plaque psoriasis and psoriatic arthritis, growing awareness and education, high prevalence of alcohol and smoking consumption. Major trends in the forecast period include product innovations, combination therapies, shift toward biologic and targeted therapies, new injectable drugs, shift towards personalized medicine. For further insights on this market, request a sample here

The tildrakizumabmarket covered in this report is segmented –
1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Other Indications
2) By Dosage Form: Injectable; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Homecare Subsegments:
1) By Plaque Psoriasis: Moderate Plaque Psoriasis; Severe Plaque Psoriasis; Treatment-Resistant Plaque Psoriasis
2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis; Axial Psoriatic Arthritis; Enthesitis-related Psoriatic Arthritis
3) By Other Indications: Inflammatory Skin Disorders; Off-Label Autoimmune Conditions; Emerging Therapeutic Applications For further insights on this market,
request a sample here

North America was the largest region in the tildrakizumab market in 2024. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in the tildrakizumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the tildrakizumab market are Sun Pharmaceutical Industries Ltd., Almirall S.A. . For further insights on this market, request a sample here.

Major trends in this market include Transforming Treatment With Monoclonal Antibody Injections. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon